Literature DB >> 23848309

Systematic analysis of RNAi reports identifies dismal commonality at gene-level and reveals an unprecedented enrichment in pooled shRNA screens.

Bhavneet Bhinder1, Hakim Djaballah.   

Abstract

RNA interference (RNAi) has opened promising avenues to better understand gene function. Though many RNAi screens report on the identification of genes, very few, if any, have been further studied and validated. Data discrepancy is emerging as one of RNAi main pitfalls. We reasoned that a systematic analysis of lethality-based screens, since they score for cell death, would examine the extent of hit discordance at inter-screen level. To this end, we developed a methodology for literature mining and overlap analysis of several screens using both siRNA and shRNA flavors, and obtained 64 gene lists censoring an initial list of 7,430 nominated genes. We further performed a comparative analysis first at a global level followed by hit re-assessment under much more stringent conditions. To our surprise, none of the hits overlapped across the board even for PLK1, which emerged as a strong candidate in siRNA screens; but only marginally in the shRNA ones. Furthermore, EIF5B emerges as the most common hit only in the shRNA screens. A highly unusual and unprecedented result was the observation that 5,269 out of 6,664 nominated genes (~80%) in the shRNA screens were exclusive to the pooled format, raising concerns as to the merits of pooled screens which qualify hits based on relative depletions, possibly due to multiple integrations per cell, data deconvolution or inaccuracies in intracellular processing causing off-target effects. Without golden standards in place, we would encourage the community to pay more attention to RNAi screening data analysis practices, bearing in mind that it is combinatorial in nature and one active siRNA duplex or shRNA hairpin per gene does not suffice credible hit nomination. Finally, we also would like to caution interpretation of pooled shRNA screening outcomes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23848309      PMCID: PMC3885821          DOI: 10.2174/13862073113169990045

Source DB:  PubMed          Journal:  Comb Chem High Throughput Screen        ISSN: 1386-2073            Impact factor:   1.339


  46 in total

1.  The contributions of dsRNA structure to Dicer specificity and efficiency.

Authors:  Annaleen Vermeulen; Linda Behlen; Angela Reynolds; Alexey Wolfson; William S Marshall; Jon Karpilow; Anastasia Khvorova
Journal:  RNA       Date:  2005-04-05       Impact factor: 4.942

2.  An arrayed genome-scale lentiviral-enabled short hairpin RNA screen identifies lethal and rescuer gene candidates.

Authors:  Bhavneet Bhinder; Christophe Antczak; Christina N Ramirez; David Shum; Nancy Liu-Sullivan; Constantin Radu; Mark G Frattini; Hakim Djaballah
Journal:  Assay Drug Dev Technol       Date:  2012-11-30       Impact factor: 1.738

3.  Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance.

Authors:  Valentin Giroux; Juan Iovanna; Jean-Charles Dagorn
Journal:  FASEB J       Date:  2006-10       Impact factor: 5.191

4.  Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance.

Authors:  Jeffrey P MacKeigan; Leon O Murphy; John Blenis
Journal:  Nat Cell Biol       Date:  2005-05-01       Impact factor: 28.824

5.  A loss-of-function RNA interference screen for molecular targets in cancer.

Authors:  Vu N Ngo; R Eric Davis; Laurence Lamy; Xin Yu; Hong Zhao; Georg Lenz; Lloyd T Lam; Sandeep Dave; Liming Yang; John Powell; Louis M Staudt
Journal:  Nature       Date:  2006-03-29       Impact factor: 49.962

6.  Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells.

Authors:  Aparna V Sarthy; Susan E Morgan-Lappe; Dorothy Zakula; Lawrence Vernetti; Mark Schurdak; Jeremy C L Packer; Mark G Anderson; Senji Shirasawa; Takehiko Sasazuki; Stephen W Fesik
Journal:  Mol Cancer Ther       Date:  2007-01       Impact factor: 6.261

7.  Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen.

Authors:  Susan E Morgan-Lappe; Lora A Tucker; Xiaoli Huang; Qian Zhang; Aparna V Sarthy; Dorothy Zakula; Lawrence Vernetti; Mark Schurdak; Jieyi Wang; Stephen W Fesik
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

8.  PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification.

Authors:  Paul D Thomas; Anish Kejariwal; Michael J Campbell; Huaiyu Mi; Karen Diemer; Nan Guo; Istvan Ladunga; Betty Ulitsky-Lazareva; Anushya Muruganujan; Steven Rabkin; Jody A Vandergriff; Olivier Doremieux
Journal:  Nucleic Acids Res       Date:  2003-01-01       Impact factor: 16.971

9.  Profiling essential genes in human mammary cells by multiplex RNAi screening.

Authors:  Jose M Silva; Krista Marran; Joel S Parker; Javier Silva; Michael Golding; Michael R Schlabach; Stephen J Elledge; Gregory J Hannon; Kenneth Chang
Journal:  Science       Date:  2008-02-01       Impact factor: 47.728

10.  Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs.

Authors:  Charles Swanton; Michela Marani; Olivier Pardo; Patricia H Warne; Gavin Kelly; Erik Sahai; Frédéric Elustondo; Jenny Chang; Jillian Temple; Ahmed A Ahmed; James D Brenton; Julian Downward; Barbara Nicke
Journal:  Cancer Cell       Date:  2007-06       Impact factor: 31.743

View more
  13 in total

Review 1.  The New State of the Art: Cas9 for Gene Activation and Repression.

Authors:  Marie F La Russa; Lei S Qi
Journal:  Mol Cell Biol       Date:  2015-09-14       Impact factor: 4.272

Review 2.  RNAi screening comes of age: improved techniques and complementary approaches.

Authors:  Stephanie E Mohr; Jennifer A Smith; Caroline E Shamu; Ralph A Neumüller; Norbert Perrimon
Journal:  Nat Rev Mol Cell Biol       Date:  2014-09       Impact factor: 94.444

Review 3.  Cell-based screening: extracting meaning from complex data.

Authors:  Steven Finkbeiner; Michael Frumkin; Paul D Kassner
Journal:  Neuron       Date:  2015-04-08       Impact factor: 17.173

Review 4.  Synthetic lethality and cancer.

Authors:  Nigel J O'Neil; Melanie L Bailey; Philip Hieter
Journal:  Nat Rev Genet       Date:  2017-06-26       Impact factor: 53.242

5.  Comparative analysis of RNAi screening technologies at genome-scale reveals an inherent processing inefficiency of the plasmid-based shRNA hairpin.

Authors:  Bhavneet Bhinder; David Shum; Hakim Djaballah
Journal:  Comb Chem High Throughput Screen       Date:  2014-02       Impact factor: 1.339

6.  Plasmid-based shRNA lentiviral particle production for RNAi applications.

Authors:  David Shum; Hakim Djaballah
Journal:  J Biomol Screen       Date:  2014-06-17

Review 7.  Synthetic Lethal Networks for Precision Oncology: Promises and Pitfalls.

Authors:  John Paul Shen; Trey Ideker
Journal:  J Mol Biol       Date:  2018-06-20       Impact factor: 5.469

8.  SIGNAL: A web-based iterative analysis platform integrating pathway and network approaches optimizes hit selection from genome-scale assays.

Authors:  Samuel Katz; Jian Song; Kyle P Webb; Nicolas W Lounsbury; Clare E Bryant; Iain D C Fraser
Journal:  Cell Syst       Date:  2021-03-24       Impact factor: 11.091

9.  Phospholipase C γ1 regulates early secretory trafficking and cell migration via interaction with p115.

Authors:  Valentina Millarte; Gaelle Boncompain; Kerstin Tillmann; Franck Perez; Elizabeth Sztul; Hesso Farhan
Journal:  Mol Biol Cell       Date:  2015-04-22       Impact factor: 4.138

10.  Discovery of a dicer-independent, cell-type dependent alternate targeting sequence generator: implications in gene silencing & pooled RNAi screens.

Authors:  Bhavneet Bhinder; David Shum; Mu Li; Glorymar Ibáñez; Alexander V Vlassov; Susan Magdaleno; Hakim Djaballah
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.